Background Preclinical studies have shown synergistic antitumour activity by inhibition of insulin-like growth factor-1 receptor (IGF-1R) and mTOR. The expression of IGF-1R seems to be crucial for this eff ect. We investigated the safety and effi cacy of the combination of the IGF-1R antibody cixutumumab and the mTOR inhibitor temsirolimus in patients with chemotherapy-refractory bone and soft-tissue sarcomas according to IGF-1R expression by immunohistochemistry.
Introduction
About 13 000 cases of soft-tissue and bone sarcoma are diagnosed annually in the USA. 1 The median survival from diagnosis for patients with metastatic disease is about 10-18 months. 2 In view of the toxicity and limited effi cacy of chemotherapy, patients with advanced and metastatic disease are appropriate candidates for investigational treatments. Insulin-like growth factor-1 (IGF-1), IGF-2, and IGF-binding protein (IGF-BP) are expressed in various sarcoma subtypes, which suggests that IGF-1 receptor (IGF-1R) inhibition might be applicable in sarcomas. 3 IGF-1R is activated by the growth factor ligands IGF-1 and IGF-2, resulting in receptor autophosphorylation, which leads to the activation of many signalling cascades, including the PI3K-Akt-mTOR pathway. Several lines of evidence have suggested that IGF-1R signalling is crucial to the biological changes in Ewing's sarcoma and that targeting IGF-1R can inhibit tumour growth. [4] [5] [6] [7] [8] However, in two large phase 2 trials in Ewing's sarcoma, treatment with IGF-1R-targeting monoclonal antibodies, R1507 and fi gitumumab, resulted in overall response rates of only 10% and 14% and median progression-free survival (PFS) of 1·3 and 1·9 months, respectively. 9, 10 Combined inhibition of both IGF-1R and mTOR signalling represents a novel approach for treatment of sarcoma. 11, 12 Blockade of mTOR alone paradoxically activates Akt. 13 This fi nding might explain the dis appointing single-drug activity with mTOR inhibitors, such as temsirolimus, in patients with soft-tissue sar coma. 14 However, IGF-1R inhibition suppresses mTOR-induced Akt activation and sensitises tumour cells to mTOR inhibitors. 13 Pretreatment of rhabdomyosarcoma cell lines with the IGF-1R antibody h7C10 resulted in blockade of rapamycin-induced Akt activation and in an enhanced antiproliferative eff ect compared with either drug alone. 12 The IGF-1R antibody R1507 similarly enhanced the eff ect of rapamycin by downregulating IGF-1R and blocking the reactivation of phosphorylated Akt (p-Akt) in a broad range of sarcoma cell lines. 15 For sarcoma cell lines in which there was no IGF-1R expression, the combination of R1507 and rapamycin was ineff ective. 15 Based on such data, phase 1 studies of the combination of IGF-1R and mTOR inhibitors in sarcoma have been undertaken. 16, 17 The fully humanised IgG1-monoclonal-antibody-targeting IGF-1R cixutumumab can be combined safely with the mTOR inhibitor temsirolimus at respective doses of 6 mg/kg and 25 mg (fl at dose) weekly. 16 We therefore initiated a phase 2 trial of cixutumumab and temsirolimus in bone and softtissue sarcoma with stratifi cation according to IGF-1R status. We hypothesised that IGF-1R expression by the tumour would be crucial to identify the clinical benefi t of this drug combination and would be independent of histological subtype. Because response to IGF-1R antibody treatment on the basis of histological subtype alone has been scarce, we believed that upfront stratifi cation by IGF-1R expression would result in an improved clinical benefi t. Therefore, rather than stratify by histological subtype, we assessed clinical benefi t according to IGF-1R expression by immuno histochemistry.
Methods

Patients
We undertook a multicentre, open-label, phase 2, nonrandomised trial in 19 cancer centres in the USA. Patients aged at least 16 years were eligible if they had an Eastern Cooperative Oncology Group performance status of 0 or 1, histologically or cytologically confi rmed sarcoma of soft tissue or bone, and measurable metastatic or locally advanced disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, and if they had received at least one but not more than four previous treatments and had adequate organ function (defi ned by a normal complete blood count [absolute neutrophil count ≥1·5 × 10⁹/L, platelet count ≥100 × 10⁹/L], liver function tests [total bilirubin ≤1·5 × institutional upper limit of normal [ULN] and aspartate aminotransferase and alanine aminotransferase ≤3 × ULN], and renal function [serum creatinine ≤1·5 × ULN). Patients with hyper glycaemia, defi ned as fasting serum glucose above 6·66 mmol/L, or those already on oral antidiabetic or insulin treatment were excluded from the study, as were those who received previous IGF-1R or mTOR inhibitors.
The study was undertaken in accordance with the Declaration of Helsinki. All patients provided written informed consent before enrolment after being informed about the purpose and the investigational nature of the study. The institutional review boards of all participating centres reviewed and approved the protocol.
Procedures
All patients had IGF-1R testing on archival tissue by immunohistochemistry at Memorial Sloan-Kettering Cancer Center (MSKCC; New York, NY, USA). Im munohistochemistry was done on 4-μm formalin-fi xed paraffi n embedded slides using pre-diluted IGF-1R antibodies (Ventana, Ventana Medical Systems, Tucson, AZ, USA) according to published methods. 18 The scoring for IGF-1R expression was quantitated on a 0-3+ scale: 0-1+, no staining or faint or weak staining; 2+, moderate staining; and 3+, strong staining. Only staining of 2+ to 3+ (cytoplasmic or membrane or both) was deemed positive. Scoring for IGF-1R expression was done by central pathology review (Cristina Antonescu, MSKCC) so as to minimise the inter-patient variability with immunohistochemistry.
Patients were assigned to one of three groups: those in group A had IGF-1R-positive sarcomas of soft tissue; those in group B had IGF-1R-positive sarcomas of bone; and those in group C had IGF-1R-negative sarcomas of bone and soft tissue. All patients received weekly treatment with cixutumumab (6 mg/kg intravenous) over 1 h followed 1 h later (30 min if the fi rst two doses were tolerated) by temsirolimus (25 mg intravenous) in 6-week cycles.
If grade 3 or 4 neutropenia or thrombocytopenia occurred, temsirolimus and cixutumumab were respectively reduced by one (20 mg and 5 mg/kg) or two (15 mg and 4 mg/kg) dose levels. For hyperglycaemia of grade 1 toxicity or greater, oral antidiabetic treatment or insulin was started. For symptomatic grade 3 or any grade 4 hyperglycaemia, cixutumumab was reduced by one or two dose levels. For any grade 1 hepatic toxicity (bilirubin, alanine aminotransferase, or aspartate aminotransferase) the temsirolimus dose was reduced immediately by two dose levels (15 mg). Hyperlipidaemia was treated with medical management rather than by dose reduction. Patients were assessed weekly for adverse events.
Clinical and radiological (contrast CT or MRI of chest, abdomen, and pelvis) assessments were obtained every 6 weeks. Plasma samples for measurement of IGF-1 and IGF-BP3 concentrations by ELISA assay (R&D Systems, Minneapolis, MN, USA) were taken before treatment and on weeks 3 and 7. Plasma measurements were a requirement at MSKCC but were optional at other sites.
All patients treated at MSKCC were required to undergo tumour biopsies before and after treatment unless deemed clinically inappropriate. Biopsies were fl ash frozen in liquid nitrogen before treatment and between weeks 2 and 3 for assessment of total IGF-1R, p-Akt, total Akt, phosphorylated S6 (p-S6), and total S6 by western blots according to standard techniques. 15 Equal loading of protein was confi rmed by tubulin and GAPDH staining, and relative protein expression was quantifi ed by densitometry assessment with ImageJ. All primary antibodies were obtained from Cell Signaling (Boston, MA, USA). The primary endpoint was PFS at 12 weeks in the fi rst 54 patients assigned to each treatment group, as assessed by RECIST 1.1. Secondary endpoints were overall survival, overall disease response, and correlation of plasma bio markers with clinical outcome. A post-hoc analysis was done by histological subtypes on progression-free survival, overall survival, and response.
Statistical analysis
Based on historical controls, a PFS of over 40% at 3 months was deemed acceptable for second-line treatment and a PFS of less than 20% was deemed unacceptable. 19 We used a Simon optimal two-stage design for every arm such that the outcome of the study was assessed by the decision rule of the study design. 20 In particular, in stage 1, 19 patients were to be accrued. If fewer than fi ve patients (26%) were progression free at 12 weeks, further accrual would cease and the combination therapy would be declared ineff ective. If at least fi ve patients in stage 1 were progression free then an additional 35 patients would be accrued in stage 2 for a total of 54 patients. If at least 16 patients were progression free at 12 weeks among the fi rst 54 patients, the arm would be judged to have a positive result and the combination therapy would be worthy of further testing. This design had a power of 0·90 for establishing the treatment eff ect for a population 12-week PFS proportion of 40% using a type I error of 0·05. The probability of stopping each arm of the study early was 67% if the population 12-week PFS proportion was 20%.
Analyses of effi cacy data were done for all patients who had received any study drug (intention-to-treat). For every arm, the proportion of patients remaining free of progression at 12 weeks was estimated and a one-sided 95% CI and a two-sided 90% CI were calculated. Median event-free times for all treated patients were estimated by the Kaplan-Meier method with a two-sided 95% CI and were compared between groups by the log-rank test with a two-sided p value. Correlation of plasma biomarkers for IGF-1 and IGF-BP3 to PFS at 12 weeks was examined by the Wilcoxon rank sum test with a twosided p value for absolute levels at baseline, week 3, or week 7 and for change of levels at week 3 or week 7 from baseline. R software (version 2.14.2) was used for all statistical analyses.
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Results
From Nov 18, 2009, to April 11, 2012, 388 patients were screened for IGF-1R expression by immunohistochemistry. Of these, 211 (54%) were IGF-1R positive and 177 (46%) were IGF-1R negative across many sarcoma subtypes (table 1) . Patients were then enrolled into a treatment group at the discretion of the treating physicians until 54 patients had been enrolled in each group. All groups met the requirements for stage 1 before enrollment continued. The remainder of the screened patients were excluded because the study arm was closed to patient accrual or the patient did not meet protocol eligibility, had poor performance status, withdrew consent, elected to seek hospice or other treatments, or for other reasons (fi gure 1). On April 6, 2011, the protocol was amended to include three additional patients in the IGF-1R-positive soft-tissue sarcoma group and nine in the IGF-1R-negative sarcoma group, giving a total of 57 patients with IGF-1R-positive soft-tissue sarcoma (group A), 54 with IGF-1R-positive bone sar coma (group B), and 63 with IGF-1R-negative sarcoma (group C). This protocol amendment was made because of over enrolment into group A (patients who consented before enrolment was halted) and on the basis of promising results in fi rst 54 patients in group C. Table 2 shows the baseline demographics and patient characteristics, including the most common histological subtypes by IGF-1R status, for all treated patients. The mean number of previous systemic regimens was two (range one to four). After the fi rst stage of enrolment, more than fi ve patients in each group were progression free at 12 weeks. By intention-to-treat analysis, of the 54 patients in each group in the original cohort (ie, before the protocol amendment), 17 patients (31%; one-sided 95% CI lower bound 21%; two-sided 90% CI 21-43) in the IGF-1R-positive soft-tissue sarcoma group, 19 patients (35%; onesided 95% CI lower bound 24%; two-sided 90% CI 24-47) in the IGF-1R-positive bone sarcoma group, and 21 patients (39%; one-sided 95% CI lower bound 28%; two-sided 90% CI 28-51) in the IGF-1R-negative group were progression free at 12 weeks.
After the protocol amendment and inclusion of additional patients, 17 of 57 patients (30%; one-sided 95% CI lower bound 20%; two-sided 90% CI 20-41) in the IGF-1R-positive soft-tissue sarcoma group and 26 of 63 (41%; one-sided 95% CI lower bound 31%; two-sided 90% CI 31-52) in the IGF-1R-negative group were progression free at 12 weeks. At the time of fi nal analysis, the median follow-up of survivors was 18·6 months (range 2·9-30·9). The median PFS by Kaplan-Meier estimates for all treated patients was 6·9 weeks (95% CI 5·9-12·0) for the IGF-1R-positive soft-tissue sarcoma group, 10·6 weeks (6·0-15·3) for the IGF-1R-positive bone sarcoma group, and 11·6 weeks (9·3-17·9) for the IGF-1R-negative group (fi gure 2A).
Based on 98 deaths and a median duration of followup of 18·6 months (range 2·9-30·9), the median overall survival in all treated patients (n=174) was 18·9 months (95% CI 13·1 to not reached [NR]) for patients with IGF-1R-positive soft-tissue sarcoma, 14·2 months (7·6 to NR) for patients with IGF-1R-positive bone sarcoma, and 14·7 months (10·6 to NR) for patients with IGF-1R-negative sarcoma; fi gure 2B). All deaths were due to disease progression.
Nine patients achieved a partial response: one (2%) of 57 patients in the IGF-1R-positive soft-tissue sarcoma group, six (11%) of 54 patients in the IGF-1R-positive bone sarcoma group, and two (3%) of 63 patients in the IGF-1R-negative group. There were no complete responses.
Analysis of plasma biomarkers in 55 patients (15 in the IGF-1R-positive soft-tissue sarcoma group, 23 in the IGF-1R-positive bone sarcoma group, and 17 in the IGF-1R-negative group) for IGF-1 and IGF-BP3 showed no correlation to PFS or overall survival (data not shown).
All patients with disease progression at week 12 had signifi cant increases in plasma biomarkers from baseline to weeks 3 or 7 (p<0·01 appendix). 32 patients (nine in the IGF-1R-positive soft-tissue sarcoma group, 16 in the IGF-1R-positive bone sarcoma group, and seven in the IGF-1R-negative group) at MSKCC had serial tumour biopsies undertaken before treatment and between weeks 2 and 3 of the fi rst cycle of therapy and analysed by western blot. Although suppression of IGF-1R and inhibition of both p-S6 and p-Akt was noted in individual patients in all treatment arms, semi-quantitative analysis did not suggest any consistent association between the percent decrease in IGF-1R, p-S6, or p-Akt expression and clinical outcome (table 3). All patients in the immunohistochemistrydefi ned IGF-1R-negative group-in which IGF-1R was assessable by western blot (fi ve of the seven)-were IGF-1R positive by western blot (table 3) .
Of 2546 adverse events reported, 214 (8%) were grade 3-4. Grade 1-2 and 3-4 events that occurred in at least 5% of all patients treated are listed by stratifi cation groups (table 4) and by histological subtype (appendix). The incidence of grade 3 and 4 events was similar between the three study arms. The most common grade 3-4 toxicities in the 174 patients were anaemia in 16 (9%) patients, hyperglycaemia in 18 (10%) patients, hypo phosphataemia in 16 (9%) patients, lymphopenia in 25 (14%) patients, oral mucositis in 19 (11%) patients, and thrombocytopenia in 19 (11%) patients. Although hyperglycaemia was noted in 119 (68%) of 174 patients, this was generally grade 1-2 and was well controlled. Of 174 patients treated on the study, 83 (48%) experienced a serious adverse event; 43 (52%) of these patients had a serious adverse event reported as possibly, probably, or defi nitely related to drug therapy. Among the serious adverse events for which a causal relation to drug therapy was suggested, only oral mucositis (12 [7%] ) and thrombocytopenia (nine [5%]) occurred in at least 5% of 174 patients treated. There were four (2%) deaths on study and all of these were attributable to disease progression. Except for one episode of hypoxia, there were no reports of pneumonitis.
91 In a post-hoc analysis, we analysed median PFS, overall survival, and response according to histological subtype and IGF-1R status. The median PFS for the most common histological subtypes were 7·5 weeks (95% CI 5·6-17·7) for Ewing's sarcoma, 6·0 weeks (5·9-15·7) for osteosarcoma, 21·4 weeks (5·7-35·4) for chondrosarcoma, 11·4 weeks (6·3-15·3) for leiomyo sarcoma, and 12·9 weeks (5·6-46·9) for undiff erentiated pleomorphic sarcoma. For patients with osteosarcoma and leiomyosarcoma, IGF-1R status did not have an eff ect on median PFS (fi gure 3A and B). However, for Ewing's sarcoma and chondrosarcoma, IGF-1R immuno histochemistry expression had a statistically signifi cant eff ect on median PFS (fi gure 3C and D). Nine (82%) of 11 IGF-1R-positive chondrosarcomas were histologically grade 2 and 3 and fi ve (56%) of these nine were dediff erentiated. For patients with Ewing's sarcoma, the median PFS was 5·7 weeks (95% CI 4·3-11·9) for those with IGF-1R-positive disease and and 17·7 weeks (9·0 to NR) for those with IGF-1R-negative disease (p=0·027, fi gure 3C). For patients with chondro sarcoma, the median PFS was 23·0 weeks (11·0 to NR) for those with IGF-1R-positive disease and 8·1 weeks (3·0 to NR) for those with IGF-1R-negative disease (p=0·048, fi gure 3D). For the eight patients with solitary fi brous tumours, the median PFS for the four patients with IGF-1R-positive disease was 89·6 weeks (4·0 to NR) and 16·1 weeks (5·0 to NR) for those with IGF-1R-negative disease, but this was not statistically signifi cantly diff erent (p=0·22). This analysis included two patients with IGF-1R-positive solitary fi brous tumours who remained on study for 126 weeks and another who remains on study for 96 weeks. Median overall survival was 16·2 months (95% CI 5·2 to NR) for Ewing's sarcoma, 14·6 months (8·6 to NR) for leiomyosarcoma, not reached (7·6 to NR) for osteosarcoma, 13·6 months (10·6 to NR) for chondrosarcoma, 15·5 months (8·5 to NR) for undiff erentiated pleomorphic sarcoma, and 18·9 months (11·9 to NR) for others (fi gure 3E). In a post-hoc analysis, patients with IGF-1R-negative Ewing's sarcoma also had a numerical but not statistically signifi cant (p=0·16) improvement in median overall survival (NR, 95% CI 16·2 to NR) when compared with those who were IGF-1R positive (14·0 months, 4·6 to NR). Figure 4 shows the waterfall plot for best RECIST response according to histology. Four of 27 (15%) patients with Ewing's sarcoma, three of 24 (13%) with osteosarcoma, one of 17 (6%) with chondrosarcoma, and one of eight (13%) with solitary fi brous tumour (hemangiopericytoma) had partial responses. There were no complete responses. Of the four patients with a diagnosis of gastrointestinal stromal tumour, one (IGF-1R positive) had a 13% decrease in tumour size from baseline as measured by RECIST.
Discussion
We undertook a phase 2 study to assess the safety and effi cacy of an IGF-1R antibody and a mTOR inhibitor in combination therapy in bone and soft-tissue sarcomas based on IGF-1R immunohistochemistry status. Toxicities were consistent with those reported in the phase 1 study of this combination. 16 The primary endpoint of PFS at 12 weeks ranged from 31% in patients with IGF-1R-positive soft-tissue sarcoma to 39% in patients with IGF-1R-negative sarcoma. Based on historical controls, a PFS in this range suggests that the combination of cixutumumab and temsirolimus is active in sarcoma. 19 12-week PFS is a widely accepted benchmark for assessment of new drugs in sarcoma. It has been the primary endpoint of several clinical trials including the single-arm phase 2 study of pazopanib in sarcoma, 21 a drug that is now approved by the US Food and Drug Administration for this disease. Additionally, the evidence of stable disease for at least 1 year in two patients with solitary fi brous tumours and partial responses in patients with Ewing's sarcoma, osteosarcoma, solitary fi brous tumour, and chondro sarcoma would support an argument that these drugs could off er disease control to subsets of patients with sarcoma (panel).
We hoped that IGF-1R expression by immunohistochemistry would be predictive of an improved outcome with therapy. The disease control noted in the IGF-1R-negative immunohistochemistry group was at least as good as that in the IGF-1R-positive groups. This inability to show an improved outcome across all tumour histological subtypes on the basis of IGF-1R expression does point out potential limitations to using IGF-1R immuno histo chemistry as a screening tool for an IGF-1R-directed treatment. This could be because of limited antibody sensitivity. Therefore, the inability to detect IGF-1R by immunohistochemistry in patients using the Ventana antibody, who were otherwise IGF-1R positive by western blot using the Cell Signaling antibody, suggests that the Ventana antibody might not be sensitive enough to detect the low levels of IGF-1R expression. By standardising our immunohistochemistry assay and by having one sarcoma pathologist for central review of all the immunohistochemistry stained slides, we tried to avoid many of the pitfalls associated with immunohistochemistry staining. These pitfalls include broad inter-laboratory variability in performance of the assay, discrepancies between laboratories with high-volume versus low-volume throughput, use of diff erent antibodies across sites, and deviations from recommended methods in the package insert leading to altered performance characteristics of the assays. Diff erent cutoff points for classifying a positive result can also aff ect interpretation of the data. In our Data are number (%). Table 4 : Adverse events of grade 1 or higher experienced by at least 5% of patients study we limited enrolment to tumour tissue that was 2-3+ by immunohistochemistry. This stringent cutoff might have excluded patients from the study who would have been otherwise IGF-1R positive. There are several pitfalls associated with western blotting, especially for the detection of phosphoproteins on tumour tissues, including the handling of the tissues, the time from tumour procurement to fl ash freezing, the amount of tumour available for analysis, and the specifi city of the antibodies used. In our study, to minimise several of these issues, we obtained tumour biopsies at only one site (MSKCC) and all samples were fl ash frozen almost immediately upon biopsy within the interventional radiology suite. For the plasma correlates (IGF-1 and IGF-BP3 by ELISA), even though they were run at one site (MSKCC), they were obtained at multiple cancer centres, leaving us susceptible to some of the same issues mentioned previously for tumour procurement.
Although there was no overall eff ect of IGF-1R expression by immunohistochemistry on outcome, a post-hoc analysis of IGF-1R immunohistochemistry according to specifi c sarcoma subtypes did reveal that patients with Ewing's sarcoma who were IGF-1R negative by immunohistochemistry had better median PFS than those who were IGF-1R positive. This fi nding suggests that in Ewing's sarcoma, with the present drug dosing (6 mg/kg), low concentrations of IGF-1 receptor might be more easily saturated than higher concentrations. Alter natively, Ewing's sarcoma with low IGF-1R immuno histochemistry expression might have less aggressive biological eff ects. However, this suggestion is con founded by the fact that IGF-1R-positive chondrosar comas still had a better median PFS over IGF-1R-negative chondrosarcomas. The higher incidence of high-grade and dediff erentiated chondrosarcomas in the IGF-1R-positive group suggests that this better outcome was not because of less aggressive histological changes. These results, relative to IGF-1R status for specifi c sarcoma histological changes, are based on small numbers and should still be considered exploratory. Pappo and colleagues 10 suggested that the moderate clinical benefi t noted with the IGF-1R antibody R1507 as a single drug in the treatment of Ewing's sarcoma could have been because of under dosing of the drug. 10 Because the minimum dose of cixutumumab needed for inhibition of IGF-1R is unknown, the dose reductions needed for cixutumumab-related toxicity could have infl uenced the outcome of the present study. The same issue applies to temsirolimus, for which we used a starting dose of 25 mg intravenous weekly. Although this dose will modulate p-S6, lower doses have not been assessed and whether lower doses will inhibit mTOR signalling is unknown. This point is particularly relevant to our study because over 50% of the patients needed a dose reduction of temsirolimus and this also could have had a negative eff ect on the primary study outcome. Therefore, without additional historical data linking the pharmacology of these drugs with pharmaco dynamic changes, especially at low doses, identifying how these dose reductions within the trial aff ected median PFS is diffi cult. However, the western blots from our study confi rmed pathway inhibition in some patients with downregulation of IGF-1R and inhibition of p-Akt and p-S6 in all arms of this study, particularly within the fi rst cycle of therapy, suggesting a suffi cient biological eff ect to inhibit IGF-1R and mTOR signalling at the recommended phase 2 dose of cixutumumab and temsirolimus in the combination therapy. Despite evidence for target inhibition within the tumours, disease control was not achieved in many of these patients. One possibility is that there might be other receptor tyrosine kinases that are activated in sarcoma that need to be targeted in concert with mTOR to maximise p-Akt inhibition. 15 However, we do not know whether pathway inhibition was sustained beyond weeks 2-3 when the matched pair biopsies were obtained, especially at later times in the trial when dose reductions for toxicity were started. We were unsuccessful in obtaining tumour tissue at the time of disease progression, and so assessment of the exact mechanism for drug resistance and tumour progression is diffi cult.
Median overall survival was over 14 months for all patients in the study. Comparison of data regarding single-drug IGF-1R targeting with other IGF-1R-mTOR combinations or even with best supportive care is diffi cult. The only comparison that can be made is with patients with Ewing's sarcoma. With R1507 alone in Ewing's sarcoma, median PFS was 5·7 weeks, the RECIST response rate was 10%, and median overall survival was 7·6 months. 10 In the phase 1, doseexpansion phase of the trial of patients with Ewing's sarcoma treated with cixutumumab and temsirolimus, there was a 29% response rate and a median overall survival of 12·6 months (median PFS not reported). 16 With cixutumumab and temsirolimus in the present trial, even though the median PFS for the whole group was 6·0 weeks, the response rate was 15% and the median overall survival was 16·2 months. Furthermore, an examination of patients with Ewing's sarcoma by IGF-1R immunohistochemistry expression suggests that pa tients who were IGF-1R negative had a better median PFS than those who were IGF-1R positive. Additionally, although not statistically signifi cant, in a post-hoc analysis, patients with IGF-1R-negative Ewing's sarcoma also had a numerical improvement in median overall survival when compared with those who were IGF-1R positive. Collectively, these results suggest that the combination therapy should be explored in future clinical studies, especially for specifi c sarcoma histological subtypes where IGF-1R immunohistochemistry status might have an eff ect on clinical benefi t and where signs of clinical response were noted (ie, Ewing's sarcoma, chondrosarcoma, and solitary fi brous tumour).
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